Publications
 (2023) Fully human monoclonal antibody targeting activated ADAM10 on colorectal cancer cells. Biomed Pharmacother. 161, 114494
 (2021) The Ephb2 Receptor Uses Homotypic, Head-to-Tail Interactions within Its Ectodomain as an Autoinhibitory Control Mechanism. Int J Mol Sci. 10.3390/ijms221910473
 (2017) Structural Basis for Regulated Proteolysis by the α-Secretase ADAM10.. Cell. 171, 1638-1648.e7
 (2016) An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth. J Exp Med. 213, 1741-57

